Skip to main content

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Written by Customer Service on . Posted in Public Companies.

MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile. Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression (NCT06342310).

Details of the presentations are as follows:

Podium Presentation
Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum Depression
Date: Friday, April 12, 2024
Time: 4:00-5:00 p.m. ET
Location: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor Level
Presenter: Dr. Robert Alexander, Chief Medical Officer of Reunion

Poster Presentation
Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum Depression
Session Date: Saturday, April 13, 2024
Session Time: 3:45-5:15 p.m. ET
Poster #: S150
Location: Westin Boston Seaport District: Grand Ballroom, Concourse Level

The poster will be available on Reunion’s website on Friday, April 12, 2024.

About Reunion Neuroscience Inc.

Reunion Neuroscience is committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for postpartum depression (PPD) and other underserved mental health disorders. The Company’s lead asset, RE104, a proprietary, potential best-in-class, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being evaluated as a potential treatment for postpartum depression, (NCT06342310), that could provide rapid symptom relief and durable efficacy. Reunion is actively investigating the use of RE104, which has a patent granted for exclusive rights for the composition of matter through 2042, in additional indications susceptible to being treated with a 5HT2A agonist molecule.

For more information about the company, visit https://reunionneuro.com.

Contact

Sarah Sutton, Argot Partners
(518) 932-3680
sarah@argotpartners.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.